The 24th Annual Scientific Retreat Recap
In October 2017, the Prostate Cancer Foundation held its 24th Annual Scientific Retreat. Like no other gathering in the industry, the retreat brings together the best and the brightest minds working on prostate cancer to share research, report on new results for patients, and participate in unprecedented collaborations. This year,. Read More
RFA Notification List Sign Up
PCF Research Awards Notification If you would like to be notified when the next research RFA is available, please provide your email address in the blue box. Go here for more information. Read More
PCF Champion: Ryan Brown
To honor his grandfather, who passed away in January, an extraordinary 12-year-old boy took on the entire NFL to raise awareness for prostate cancer. Read More
New Clinical Trial Methods Accelerate Research and Development
Prostate cancer can be slow to progress, frustrating the development of new therapies for patients with early, high-risk disease. New results from ICECaP (Intermediate Clinical Endpoints for Cancer of the Prostate), a PCF-supported initiative led by Dr. Christopher Sweeney, will cut the time required to assess new therapies for aggressive. Read More
Guys: Don’t Put it Off Like I Did. Get Checked!
While each patient’s battle with prostate cancer is an individual one, my experience is hardly unique. My story began 4 years ago, back in 2011, when my wife Susan literally begged me to see a doctor for a physical exam. At the time, I was dismissive—even incredulous at this suggestion—even though 2 of my close relatives, my. Read More
Progress Report: Thomas Guzzo, MD, MPH
Investigator: Thomas Guzzo, MD, MPH – Assistant Professor, University of Pennsylvania Reducing Morbidity from Surgery and Physician Counseling of Treatment Costs Dr. Guzzo has had a very prolific second year as a PCF Young Investigator as evidenced by his publication of ten scientific and clinical reports. His primary research aims. Read More
Progress Report: Steven Frank, MD
Investigator: Steven Frank, MD– Assistant Professor, University of Texas, M.D. Anderson Cancer Center C4 and MRI-based Prostate Brachytherapy Brachytherapy is a form of radiotherapy where a radiation source, called “seeds”, is precisely implanted into the prostate such that emitted radiation will abolish the tumor. Recent technological advances have increased the. Read More
Progress Report: Adam S. Feldman, MD, MPH
Investigator: Adam S. Feldman, MD, MPH–Assistant Professor of Surgery, Massachusetts General Hospital, Harvard School of Medicine Active Surveillance: Identifying When to Treat and When Not to Treat In 2010 nearly 218,000 men will be diagnosed with prostate cancer in the United States. However, ~50% of those men will have low. Read More
Progress Report: Eleni Efstathiou, MD, Ph.D
Investigator: Eleni Efstathiou, MD, PhD – Assistant Professor, University of Texas, M.D. Anderson Cancer Center Biomarker Driven Application of Therapy Androgens (male hormones such as testosterone) fuel prostate cancer growth and survival. Androgens are synthesized in the testis and adrenal glands. Therapeutic agents that block the production of androgens (androgen. Read More
Progress Report: Scott Dehm, Ph.D
Investigator: Scott Dehm, PhD – Assistant Professor, University of Minnesota Mechanisms of Androgen Receptor (AR) Activation in Prostate Cancer The standard first line treatment strategy for metastatic prostate cancer is androgen (male hormones) deprivation therapy, such as Lupron, which reduces the level of circulating testosterone (type of androgen), or such. Read More